Lincoln Pharmaceuticals Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
LINCOLN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lincoln Pharmaceuticals has submitted a regulatory disclosure to the stock exchange under SEBI's Substantial Acquisition of Shares and Takeovers Regulations. This is a routine filing required from promoters or acquirers holding 5% or more shares in the company. The disclosure typically covers shareholding details and any encumbrances (such as pledges) on those shares. No specific numbers, pledge amounts, or stake changes are mentioned in the headline filing itself. Investors would need to view the full disclosure document to see actual shareholding and encumbrance figures.
This is largely a routine compliance filing and is unlikely to move the stock on its own. However, the underlying disclosure could reveal important information about promoter holdings or pledged shares that may affect investor sentiment if the details are material.